Skip to main content
Top

Hint

Swipe to navigate through the chapters of this book

2016 | OriginalPaper | Chapter

3. Anwendende Sektoren und Märkte der Biotechnologie

Author : Julia Schüler

Published in: Die Biotechnologie-Industrie

Publisher: Springer Berlin Heidelberg

Zusammenfassung

Als Querschnittstechnologie wirkt die Biotechnologie beziehungsweise ihre wirtschaftliche Anwendung breit in verschiedene Einsatzfelder. Diese reichen von der pharmazeutischen über die chemische Industrie, den Agrar- und Lebensmittelsektor bis hinein in den Umweltschutz. Dadurch können wiederum viele andere produzierende Gewerbe indirekt aus der Biotechnologie Nutzen ziehen, wie zum Beispiel die Automobilindustrie. Den Anwendungsbereichen wurden nach und nach „passende“ Farben zugeordnet: Die „Rote Biotechnologie“ für die Anwendungen im Bereich der Medizin (hauptsächlich Pharmazeutika und Diagnostika), die „Weiße Biotechnologie“ für den Einsatz in der industriellen, vor allem chemischen Produktion, die „Graue Biotechnologie“ für den Umweltschutz sowie die „Grüne Biotechnologie“ für Produkte oder Problemlösungen im Agrarsektor. Neben Beispielen zu Anwendungen und Marktdaten der Roten Biotechnologie bietet das Kapitel einen Exkurs zur Medikamenten-Entwicklung. Es wird vor allem auf die Faktoren Kosten, Dauer sowie Risiko eingegangen. Zudem werden aktuelle Themen wie Biosimilars, Immun- und Gentherapie oder die personalisierte Medizin ausführlich behandelt. Die Ausführungen zur Weißen Biotechnologie umfassen unter anderem Erläuterungen zu Bioplastik und Biosprit. Zu Letzteren kann aufgezeigt werden, dass die Biotechnologie Lösungen bereithält, die eine „Tank versus Teller“-Diskussion im Keim ersticken kann. Auch in der Grünen Biotechnologie ermöglicht der technische Fortschritt neuartige Ansätze, die die bisherigen Verfahren der Pflanzenzüchtung erweitern.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Literature
go back to reference Adams CP, Brantner VV (2006) Estimating the cost of new drug development: is it really $802 million? Health Aff (Millwood) 25:420–428 CrossRef Adams CP, Brantner VV (2006) Estimating the cost of new drug development: is it really $802 million? Health Aff (Millwood) 25:420–428 CrossRef
go back to reference Ai M, Curran MA (2015) Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother. online, Ausgabe 01/2015. doi:10.1007/s00262-014-1650-8 PubMed Ai M, Curran MA (2015) Immune checkpoint combinations from mouse to man. Cancer Immunol Immunother. online, Ausgabe 01/2015. doi:10.1007/s00262-014-1650-8 PubMed
go back to reference Amplion (2013) Commercial Trends for Biomarker-Based IVD Tests (2003–2012). Amplion Research, Bend Amplion (2013) Commercial Trends for Biomarker-Based IVD Tests (2003–2012). Amplion Research, Bend
go back to reference Arlington S (2012) From vision to decision. Pharma 2020. PricewaterhouseCoopers (PwC), London Arlington S (2012) From vision to decision. Pharma 2020. PricewaterhouseCoopers (PwC), London
go back to reference Beier W (2009) Biologisch abbaubare Kunststoffe. Umweltbundesamt, Dessau-Roßlau Beier W (2009) Biologisch abbaubare Kunststoffe. Umweltbundesamt, Dessau-Roßlau
go back to reference Bernstein Research (2014) Biosimilars: Commercial Perspective. Vortrag vom 04.02.2014 von Ronny Gal, gehalten auf der Veranstaltung „Follow-On Biologics Workshop. Impact of Recent Legislative and Regulatory Naming Proposals on Competition“ der US Federal Trade Commission, Washington Bernstein Research (2014) Biosimilars: Commercial Perspective. Vortrag vom 04.02.2014 von Ronny Gal, gehalten auf der Veranstaltung „Follow-On Biologics Workshop. Impact of Recent Legislative and Regulatory Naming Proposals on Competition“ der US Federal Trade Commission, Washington
go back to reference Biosimilarz (2015) Approved Biosimilars. . Zugegriffen: 30. Juni 2015 Biosimilarz (2015) Approved Biosimilars. . Zugegriffen: 30. Juni 2015
go back to reference Bourgoin AF, Nuskey B (2013) An outlook on US biosimilar competition. Thomson Reuters, Philadelphia Bourgoin AF, Nuskey B (2013) An outlook on US biosimilar competition. Thomson Reuters, Philadelphia
go back to reference Braun M, Teichert O, Zweck A (2006) Biokatalyse in der industriellen Produktion. Fakten und Potenziale zur weißen Biotechnologie. Zukünftige Technologien Consulting (ZTC) der VDI Technologiezentrum GmbH, Düsseldorf Braun M, Teichert O, Zweck A (2006) Biokatalyse in der industriellen Produktion. Fakten und Potenziale zur weißen Biotechnologie. Zukünftige Technologien Consulting (ZTC) der VDI Technologiezentrum GmbH, Düsseldorf
go back to reference Brill A (2015) The economic viability of a U.S. biosimilars industry. Matrix Global Advisors, Washington Brill A (2015) The economic viability of a U.S. biosimilars industry. Matrix Global Advisors, Washington
go back to reference Carey J (2014) A technology optimist but a policy pessimist. Carbon pricing holds the key to success in the fight against climate change, says gene sequencing pioneer J. Craig Venter. In: Edmondson G (Hrsg) Europe’s Energy Challenge, a Science|Business special report. Science|Business Publishing, Brussels, S 16–19 Carey J (2014) A technology optimist but a policy pessimist. Carbon pricing holds the key to success in the fight against climate change, says gene sequencing pioneer J. Craig Venter. In: Edmondson G (Hrsg) Europe’s Energy Challenge, a Science|Business special report. Science|Business Publishing, Brussels, S 16–19
go back to reference CEFIC (2014) Landscape of the European Chemical Industry. The European Chemical Industry Council, Brüssel CEFIC (2014) Landscape of the European Chemical Industry. The European Chemical Industry Council, Brüssel
go back to reference Chisti Y (2013) Constraints to commercialization of algal fuels. J Biotechnol 167:201–214. doi:10.1016/j.jbiotec.2013.07.020 CrossRefPubMed Chisti Y (2013) Constraints to commercialization of algal fuels. J Biotechnol 167:201–214. doi:10.1016/j.jbiotec.2013.07.020 CrossRefPubMed
go back to reference Civan A, Köksal B (2010) The effect of newer drugs on health spending: do they really increase the costs? Health Econ 19:581–595. doi:10.1002/hec.1494 PubMed Civan A, Köksal B (2010) The effect of newer drugs on health spending: do they really increase the costs? Health Econ 19:581–595. doi:10.1002/hec.1494 PubMed
go back to reference Dalgaard K, Evers M, Santos da Silva J (2013) Biosimilars seven years on: where are we and what’s next? McKinsey & Company, New York Dalgaard K, Evers M, Santos da Silva J (2013) Biosimilars seven years on: where are we and what’s next? McKinsey & Company, New York
go back to reference DECHEMA (2004) Weiße Biotechnologie: Chancen für Deutschland. DECHEMA, Frankfurt a. M. DECHEMA (2004) Weiße Biotechnologie: Chancen für Deutschland. DECHEMA, Frankfurt a. M.
go back to reference DECHEMA (2014) Biotechnologie – der Schlüssel zur Bioökonomie. DECHEMA, Frankfurt a. M. DECHEMA (2014) Biotechnologie – der Schlüssel zur Bioökonomie. DECHEMA, Frankfurt a. M.
go back to reference Deloitte (2013) Measuring the return from pharmaceutical innovation 2013. Weathering the storm? Deloitte, London Deloitte (2013) Measuring the return from pharmaceutical innovation 2013. Weathering the storm? Deloitte, London
go back to reference Deutsche Rheuma-Liga (2014) Positionierung der Deutschen Rheuma-Liga Bundesverband e. V. zur Einführung von Biosimilars in Deutschland. Deutsche Rheuma-Liga Bundesverband e. V., Bonn Deutsche Rheuma-Liga (2014) Positionierung der Deutschen Rheuma-Liga Bundesverband e. V. zur Einführung von Biosimilars in Deutschland. Deutsche Rheuma-Liga Bundesverband e. V., Bonn
go back to reference DiMasi JA (2014) Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. R&D Cost Study Briefing. Tufts Center for the Study of Drug Development. Boston, MA, November 18, 2014 DiMasi JA (2014) Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. R&D Cost Study Briefing. Tufts Center for the Study of Drug Development. Boston, MA, November 18, 2014
go back to reference DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different? Manage Decis Econ 28:469–479. doi:10.1002/mde.1360 CrossRef DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different? Manage Decis Econ 28:469–479. doi:10.1002/mde.1360 CrossRef
go back to reference DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10:107–142. doi:10.1016/0167-6296(91)90001-4 CrossRefPubMed DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10:107–142. doi:10.1016/0167-6296(91)90001-4 CrossRefPubMed
go back to reference DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185. doi:10.1016/S0167-6296(02)00126-1 CrossRefPubMed DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151–185. doi:10.1016/S0167-6296(02)00126-1 CrossRefPubMed
go back to reference Dingermann T, Zündorf I (2014) Was sind Biosimilars? In: Bretthauer B (Hrsg) Biosimilars – Ein Handbuch. Pro Generika e. V., Berlin, S 4–29 Dingermann T, Zündorf I (2014) Was sind Biosimilars? In: Bretthauer B (Hrsg) Biosimilars – Ein Handbuch. Pro Generika e. V., Berlin, S 4–29
go back to reference Donner S, Boeing N, Samulat G (2013) Lässt sich Biosprit herstellen, ohne Nahrungsmittel zu verwenden? Technology Review Special Energie vom 14.02.2013. S 102–103 Donner S, Boeing N, Samulat G (2013) Lässt sich Biosprit herstellen, ohne Nahrungsmittel zu verwenden? Technology Review Special Energie vom 14.02.2013. S 102–103
go back to reference Downing NS, Aminawung JA, Shah ND, Krumholz, Ross JS (2014) Clinical trial evidence supporting FDA approval of novel therapeutics, 2005–2012. JAMA 311:368–377. doi:10.1001/jama.2013.282034 Downing NS, Aminawung JA, Shah ND, Krumholz, Ross JS (2014) Clinical trial evidence supporting FDA approval of novel therapeutics, 2005–2012. JAMA 311:368–377. doi:10.1001/jama.2013.282034
go back to reference DPWB (2008) Weiße Biotechnologie – die Erfolgsgeschichte geht weiter. Nationale Plattform Weiße Biotechnologie (DPWB, heute IWBio – Industrieverbund Weiße Biotechnologie), Berlin DPWB (2008) Weiße Biotechnologie – die Erfolgsgeschichte geht weiter. Nationale Plattform Weiße Biotechnologie (DPWB, heute IWBio – Industrieverbund Weiße Biotechnologie), Berlin
go back to reference Dürre P (2013) Technische Alkohole und Ketone. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 71–89 CrossRef Dürre P (2013) Technische Alkohole und Ketone. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 71–89 CrossRef
go back to reference Eckhardt E, Navarini AA, Recher A, Rippe KP, Rütsche B, Telser H, Marti M (2014) Personalisierte Medizin. Studie TA-SWISS 61/2014 des Zentrums für Technikfolgen-Abschätzung. vdf Hochschulverlag AG, ETH Zürich Eckhardt E, Navarini AA, Recher A, Rippe KP, Rütsche B, Telser H, Marti M (2014) Personalisierte Medizin. Studie TA-SWISS 61/2014 des Zentrums für Technikfolgen-Abschätzung. vdf Hochschulverlag AG, ETH Zürich
go back to reference ECO SYS (2011) Die Wettbewerbsfähigkeit der Bundesrepublik Deutschland als Standort für die Fermentationsindustrie im internationalen Vergleich. ECO SYS GmbH, Schopfheim ECO SYS (2011) Die Wettbewerbsfähigkeit der Bundesrepublik Deutschland als Standort für die Fermentationsindustrie im internationalen Vergleich. ECO SYS GmbH, Schopfheim
go back to reference Eggeling (2013) Aminosäuren. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 109–126 CrossRef Eggeling (2013) Aminosäuren. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 109–126 CrossRef
go back to reference Eikmanns B, Eikmanns M (2013) Geschichtlicher Überblick. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 1–17 CrossRef Eikmanns B, Eikmanns M (2013) Geschichtlicher Überblick. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 1–17 CrossRef
go back to reference van Erp P, Bloomer G, Wilkinson R, Wiedenheft B (2015) The history and market impact of CRISPR RNA-guided nucelases. Curr Opin Virol 12:85–90. doi:10.1016/j.coviro.2015.03.011 CrossRefPubMedPubMedCentral van Erp P, Bloomer G, Wilkinson R, Wiedenheft B (2015) The history and market impact of CRISPR RNA-guided nucelases. Curr Opin Virol 12:85–90. doi:10.1016/j.coviro.2015.03.011 CrossRefPubMedPubMedCentral
go back to reference EuropaBio (2011) Industrial or White Biotechnology. A driver of sustainable growth in Europe. EuropaBio, Brüssel EuropaBio (2011) Industrial or White Biotechnology. A driver of sustainable growth in Europe. EuropaBio, Brüssel
go back to reference European Bioplastics (2013) Bioplastics facts and figures. European Bioplastics e. V., Berlin European Bioplastics (2013) Bioplastics facts and figures. European Bioplastics e. V., Berlin
go back to reference EvaluatePharma (2009) World Preview to 2014. EvaluatePharma, London EvaluatePharma (2009) World Preview to 2014. EvaluatePharma, London
go back to reference EvaluatePharma (2010) World Preview to 2016. EvaluatePharma, London EvaluatePharma (2010) World Preview to 2016. EvaluatePharma, London
go back to reference EvaluatePharma (2012a) Embracing the patent cliff. World Preview 2018. EvaluatePharma, London EvaluatePharma (2012a) Embracing the patent cliff. World Preview 2018. EvaluatePharma, London
go back to reference EvaluatePharma (2012b) Surveying tomorrow’s BioPharma landscape. The NASDAQ Biotech Index Up Close. EvaluatePharma, London EvaluatePharma (2012b) Surveying tomorrow’s BioPharma landscape. The NASDAQ Biotech Index Up Close. EvaluatePharma, London
go back to reference EvaluatePharma (2014a) World Preview 2014. Outlook to 2020. EvaluatePharma, London EvaluatePharma (2014a) World Preview 2014. Outlook to 2020. EvaluatePharma, London
go back to reference EvaluatePharma (2014b) Pharma & Biotech 2015 Preview. EvaluatePharma, London EvaluatePharma (2014b) Pharma & Biotech 2015 Preview. EvaluatePharma, London
go back to reference EvaluatePharma (2015b) World Preview 2015. Outlook to 2020. EvaluatePharma, London EvaluatePharma (2015b) World Preview 2015. Outlook to 2020. EvaluatePharma, London
go back to reference Evens R (2013) Biotech products in Big Pharma clinical pipelines have grown dramatically. Tufts Center for the Study of Drug Development Impact Report 15(6). Tufts University, Boston Evens R (2013) Biotech products in Big Pharma clinical pipelines have grown dramatically. Tufts Center for the Study of Drug Development Impact Report 15(6). Tufts University, Boston
go back to reference Evens R, Kaitin K (2015) The evolution of biotechnology and its impact on health care. Health Aff 34:210–219. doi:10.1377/hlthaff.2014.1023 CrossRef Evens R, Kaitin K (2015) The evolution of biotechnology and its impact on health care. Health Aff 34:210–219. doi:10.1377/hlthaff.2014.1023 CrossRef
go back to reference EY (2014) Beyond borders – Global Biotechnology Report 2014. EY, Boston EY (2014) Beyond borders – Global Biotechnology Report 2014. EY, Boston
go back to reference Fernandez-Cornejo J, Wechsler S, Livingston M, Mitchell L (2014) Genetically engineered crops in the United States. ERR-162 United States Department of Agriculture, Economic Research Service, Washington Fernandez-Cornejo J, Wechsler S, Livingston M, Mitchell L (2014) Genetically engineered crops in the United States. ERR-162 United States Department of Agriculture, Economic Research Service, Washington
go back to reference Festel G (2010) Industry structure and business models for industrial biotechnology. Vortrag im Rahmen des OECD Workshop on the Outlook on industrial biotechnology am 14.01.2010 in Wien Festel G (2010) Industry structure and business models for industrial biotechnology. Vortrag im Rahmen des OECD Workshop on the Outlook on industrial biotechnology am 14.01.2010 in Wien
go back to reference Festel G, Detzel C, Maas R (2012) Industrial biotechnology – markets and industry structure. J Comm Biotechnol 18:11–21. doi:10.5912/jcb.478 CrossRef Festel G, Detzel C, Maas R (2012) Industrial biotechnology – markets and industry structure. J Comm Biotechnol 18:11–21. doi:10.5912/jcb.478 CrossRef
go back to reference Formycon (2013) 21 century biosimilars. Geschäftsbericht 2013. Formycon AG, Martinsried bei München Formycon (2013) 21 century biosimilars. Geschäftsbericht 2013. Formycon AG, Martinsried bei München
go back to reference Gabrielczyk T (2015a) Grüne Gentechnik – später Triumph für die Biotechnologie. Life Sciences Magazin |transkript 5/2015 Gabrielczyk T (2015a) Grüne Gentechnik – später Triumph für die Biotechnologie. Life Sciences Magazin |transkript 5/2015
go back to reference Gabrielczyk T (2015b) The guidebook to rewriting the genome. Life Sciences and Industry Magazine European Biotechnology. Spring Edition 2015 Gabrielczyk T (2015b) The guidebook to rewriting the genome. Life Sciences and Industry Magazine European Biotechnology. Spring Edition 2015
go back to reference Getz KA, Kaitin KI (2015) Why is the pharmaceutical and biotechnology industry struggling? In: Schüler P, Buckley BM (Hrsg) Re-engineering clinical trials. Best practices for streamlining the development process. Elsevier, London, S 3–15 CrossRef Getz KA, Kaitin KI (2015) Why is the pharmaceutical and biotechnology industry struggling? In: Schüler P, Buckley BM (Hrsg) Re-engineering clinical trials. Best practices for streamlining the development process. Elsevier, London, S 3–15 CrossRef
go back to reference Grabowski HG, Guha R, Salgado M (2014) Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff 33:1048–1057. doi:10.1377/hlthaff.2013.0862 CrossRef Grabowski HG, Guha R, Salgado M (2014) Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff 33:1048–1057. doi:10.1377/hlthaff.2013.0862 CrossRef
go back to reference Hansen RW (1979) The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In: Chien RI (Hrsg) Issues in pharmaceutical economics. Lexington Books, Lexington, S 151–187 Hansen RW (1979) The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In: Chien RI (Hrsg) Issues in pharmaceutical economics. Lexington Books, Lexington, S 151–187
go back to reference Haustein R, de Millas C, Höer A, Häussler B (2012) Saving money in the European healthcare systems with biosimilars. GaBI J 1:120–126. doi:10.5639/gabij.2012.0103.036 CrossRef Haustein R, de Millas C, Höer A, Häussler B (2012) Saving money in the European healthcare systems with biosimilars. GaBI J 1:120–126. doi:10.5639/gabij.2012.0103.036 CrossRef
go back to reference Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 31:40–51. doi:10.1038/nbt.2786 CrossRef Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 31:40–51. doi:10.1038/nbt.2786 CrossRef
go back to reference Hermann BG, Dornburg V, Patel MK (2010) Environmental and economic aspects of industrial biotechnology. In: Soetaert W (Hrsg) Industrial biotechnology. Sustainable growth and economic success. Wiley, Weinheim, S 433–455 CrossRef Hermann BG, Dornburg V, Patel MK (2010) Environmental and economic aspects of industrial biotechnology. In: Soetaert W (Hrsg) Industrial biotechnology. Sustainable growth and economic success. Wiley, Weinheim, S 433–455 CrossRef
go back to reference von Holleben M, Pani M, Heinemann A (2011) Medizinische Biotechnologie in Deutschland 2011. Biopharmazeutika: Wirtschaftsdaten und Nutzen der Personalisierten Medizin. The Boston Consulting Group, München von Holleben M, Pani M, Heinemann A (2011) Medizinische Biotechnologie in Deutschland 2011. Biopharmazeutika: Wirtschaftsdaten und Nutzen der Personalisierten Medizin. The Boston Consulting Group, München
go back to reference IBM (2012) Redefining value and success in healthcare. IBM Corporation, Somers IBM (2012) Redefining value and success in healthcare. IBM Corporation, Somers
go back to reference IMS Health (2011) Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health, London IMS Health (2011) Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health, London
go back to reference Kaitin KI, DiMasi JA (2011) Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther 89:183–188. doi:10.1038/clpt.2010.286 CrossRefPubMed Kaitin KI, DiMasi JA (2011) Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther 89:183–188. doi:10.1038/clpt.2010.286 CrossRefPubMed
go back to reference Kasenda B, von Elm E, You J et al (2014) Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 311:1045–1051. doi:10.1001/jama.2014.1361 CrossRefPubMed Kasenda B, von Elm E, You J et al (2014) Prevalence, characteristics, and publication of discontinued randomized trials. JAMA 311:1045–1051. doi:10.1001/jama.2014.1361 CrossRefPubMed
go back to reference Kinch M (2014) The rise (and decline?) of biotechnology. Drug Discov Today 19:1686–1690. doi:10.1016/j.drudis.2014.04.006 CrossRefPubMed Kinch M (2014) The rise (and decline?) of biotechnology. Drug Discov Today 19:1686–1690. doi:10.1016/j.drudis.2014.04.006 CrossRefPubMed
go back to reference Kitterman DR, Cheng SK, Dilts DM, Orwoll ES (2012) The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med 86:1360–1366. doi:10.1097/ACM.0b013e3182306440 CrossRef Kitterman DR, Cheng SK, Dilts DM, Orwoll ES (2012) The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. Acad Med 86:1360–1366. doi:10.1097/ACM.0b013e3182306440 CrossRef
go back to reference Kling J (2014) Fresh from the biotech pipeline – 2013. Nat Biotechnol 32:121–124. doi:10.1038/nbt.2811 CrossRefPubMed Kling J (2014) Fresh from the biotech pipeline – 2013. Nat Biotechnol 32:121–124. doi:10.1038/nbt.2811 CrossRefPubMed
go back to reference Lichtenberg FR (2001) Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 20:241–251. doi:10.1377/hlthaff.20.5.241 CrossRef Lichtenberg FR (2001) Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 20:241–251. doi:10.1377/hlthaff.20.5.241 CrossRef
go back to reference Lichtenberg FR (2002) Sources of U.S. longevity increase, 1960–1997. NBER Working Paper No. 8755. National Bureau of Economic Research, Cambridge Lichtenberg FR (2002) Sources of U.S. longevity increase, 1960–1997. NBER Working Paper No. 8755. National Bureau of Economic Research, Cambridge
go back to reference Lichtenberg FR (2009) The quality of medical care, behavioral risk factors, and longevity growth. NBER Working Paper No. 15068. National Bureau of Economic Research, Cambridge Lichtenberg FR (2009) The quality of medical care, behavioral risk factors, and longevity growth. NBER Working Paper No. 15068. National Bureau of Economic Research, Cambridge
go back to reference Lichtenberg FR (2010) Has medical innovation reduced cancer mortality? NBER Working Paper No. 15880. Revised Oktober 2013. National Bureau of Economic Research, Cambridge Lichtenberg FR (2010) Has medical innovation reduced cancer mortality? NBER Working Paper No. 15880. Revised Oktober 2013. National Bureau of Economic Research, Cambridge
go back to reference Lichtenberg FR (2011) Despite steep costs, payments for new cancer drugs make economic sense. Nat Med 17:244 CrossRefPubMed Lichtenberg FR (2011) Despite steep costs, payments for new cancer drugs make economic sense. Nat Med 17:244 CrossRefPubMed
go back to reference Lichtenberg FR (2014) Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009. Health Policy Technol 3:36–58. doi:10.1016/j.hlpt.2013.09.005 CrossRef Lichtenberg FR (2014) Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009. Health Policy Technol 3:36–58. doi:10.1016/j.hlpt.2013.09.005 CrossRef
go back to reference Long G, Works J (2013) Innovation in the biopharmaceutical pipeline: a multidimensional view. Analysis Group, Boston Long G, Works J (2013) Innovation in the biopharmaceutical pipeline: a multidimensional view. Analysis Group, Boston
go back to reference Lorenz HM (2002) Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther 4:185–190 PubMed Lorenz HM (2002) Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther 4:185–190 PubMed
go back to reference Lücke J, Bädeker M, Hildinger M (2014) Medizinische Biotechnologie in Deutschland 2014. Biopharmazeutika: Wirtschaftsdaten und Nutzen für Patienten mit seltenen Erkrankungen. Bericht im Auftrag des vfa. The Boston Consulting Group, München Lücke J, Bädeker M, Hildinger M (2014) Medizinische Biotechnologie in Deutschland 2014. Biopharmazeutika: Wirtschaftsdaten und Nutzen für Patienten mit seltenen Erkrankungen. Bericht im Auftrag des vfa. The Boston Consulting Group, München
go back to reference Marschall L (2000) Im Schatten der chemischen Synthese. Industrielle Biotechnologie in Deutschland (1900–1970). Campus, Frankfurt a. M. Marschall L (2000) Im Schatten der chemischen Synthese. Industrielle Biotechnologie in Deutschland (1900–1970). Campus, Frankfurt a. M.
go back to reference Maurer KH, Elleuche S, Antranikian G (2013) Enzyme. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 205–224 CrossRef Maurer KH, Elleuche S, Antranikian G (2013) Enzyme. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 205–224 CrossRef
go back to reference Mestre-Ferrandiz J, Sussex J, Towse A (2012) The R&D cost of a new medicine. Office of Health Economics, London Mestre-Ferrandiz J, Sussex J, Towse A (2012) The R&D cost of a new medicine. Office of Health Economics, London
go back to reference Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D (2011) The cost of drug development: a systematic review. Health Policy 100:4–17. doi:10.1016/j.healthpol.2010.12.002 CrossRefPubMed Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D (2011) The cost of drug development: a systematic review. Health Policy 100:4–17. doi:10.1016/j.healthpol.2010.12.002 CrossRefPubMed
go back to reference Mulcahy AW, Predmore Z, Mattke S (2014) The cost savings potential of biosimilar drugs in the United States. RAND Corporation, Santa Monica Mulcahy AW, Predmore Z, Mattke S (2014) The cost savings potential of biosimilar drugs in the United States. RAND Corporation, Santa Monica
go back to reference Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968. doi:10.1038/nrd2961 CrossRefPubMed Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968. doi:10.1038/nrd2961 CrossRefPubMed
go back to reference Ndegwa S, Quansah K (2013) Subsequent entry biologics – emerging trends in regulatory and health technology assessment frameworks [Environmental Scan 43, ES0284]. Canadian Agency for Drugs and Technologies in Health, Ottawa Ndegwa S, Quansah K (2013) Subsequent entry biologics – emerging trends in regulatory and health technology assessment frameworks [Environmental Scan 43, ES0284]. Canadian Agency for Drugs and Technologies in Health, Ottawa
go back to reference Nicolaides NC, O’Shannessy DJ, Albone E, Grasso L (2014) Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy. Front Oncol 4:141. doi:10.3389/fonc.2014.00141 CrossRefPubMedPubMedCentral Nicolaides NC, O’Shannessy DJ, Albone E, Grasso L (2014) Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy. Front Oncol 4:141. doi:10.3389/fonc.2014.00141 CrossRefPubMedPubMedCentral
go back to reference nova-Institut (2013) Bio-based polymers in the world. Capacities, production and applications: status quo and trends towards 2020. nova-Institut, Hürth nova-Institut (2013) Bio-based polymers in the world. Capacities, production and applications: status quo and trends towards 2020. nova-Institut, Hürth
go back to reference Otto R, Santagostino A, Schrader U (2014) From science to operations. Questions, choices and strategies for success in biopharma. McKinsey & Company, New York Otto R, Santagostino A, Schrader U (2014) From science to operations. Questions, choices and strategies for success in biopharma. McKinsey & Company, New York
go back to reference Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214. doi:10.1038/nrd3078 PubMed Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214. doi:10.1038/nrd3078 PubMed
go back to reference Pavic M, Pfeil AM, Szucs TD (2014) Estimating the potential annual welfare impact of innovative drugs in use in Switzerland. Front Public Health 2:48. doi:10.3389/fpubh.2014.00048 CrossRefPubMedPubMedCentral Pavic M, Pfeil AM, Szucs TD (2014) Estimating the potential annual welfare impact of innovative drugs in use in Switzerland. Front Public Health 2:48. doi:10.3389/fpubh.2014.00048 CrossRefPubMedPubMedCentral
go back to reference PhRMA (2013) Medicines in development: Biologics. Pharmaceutical Research and Manufacturers of America, Washington PhRMA (2013) Medicines in development: Biologics. Pharmaceutical Research and Manufacturers of America, Washington
go back to reference PhRMA (2015) 2015 biopharmaceutical research industry profile. Pharmaceutical Research and Manufacturers of America, Washington PhRMA (2015) 2015 biopharmaceutical research industry profile. Pharmaceutical Research and Manufacturers of America, Washington
go back to reference Pindyck RS, Rubinfeld DL (2013) Mikroökonomie. Pearson Studium, München Pindyck RS, Rubinfeld DL (2013) Mikroökonomie. Pearson Studium, München
go back to reference Plieth J (2015) Not for the faint of CAR-T. The CAR-T therapy landscape in 2015. Evaluate, London Plieth J (2015) Not for the faint of CAR-T. The CAR-T therapy landscape in 2015. Evaluate, London
go back to reference PMC (2014) The case for personalized medicine, 4. Aufl. The Personalized Medicine Coalition (PMC), Washington PMC (2014) The case for personalized medicine, 4. Aufl. The Personalized Medicine Coalition (PMC), Washington
go back to reference PMC (2015) Personalized medicine by the numbers. The Personalized Medicine Coalition (PMC), Washington PMC (2015) Personalized medicine by the numbers. The Personalized Medicine Coalition (PMC), Washington
go back to reference Rader RA (2008) (Re)defining biopharmaceutical. Nat Biotechnol 26:743–751. doi:10.1038/nbt0708-743 CrossRefPubMed Rader RA (2008) (Re)defining biopharmaceutical. Nat Biotechnol 26:743–751. doi:10.1038/nbt0708-743 CrossRefPubMed
go back to reference Rader RA (2013a) FDA Biopharmaceutical product approvals and trends in 2012. BioProcess Int 11:18–27 Rader RA (2013a) FDA Biopharmaceutical product approvals and trends in 2012. BioProcess Int 11:18–27
go back to reference Rader RA (2013b) An analysis of the US biosimilars development pipeline and likely market evolution. BioProcess Int 11:16–23 Rader RA (2013b) An analysis of the US biosimilars development pipeline and likely market evolution. BioProcess Int 11:16–23
go back to reference Robertson DE, Jacobson SE, Morgan F, Berry B, Church GM, Afeyan NB (2011) A new dawn for industrial photosynthesis. Photosynth Res 107:269–277. doi:10.1007/s11120-011-9631-7 CrossRefPubMedPubMedCentral Robertson DE, Jacobson SE, Morgan F, Berry B, Church GM, Afeyan NB (2011) A new dawn for industrial photosynthesis. Photosynth Res 107:269–277. doi:10.1007/s11120-011-9631-7 CrossRefPubMedPubMedCentral
go back to reference Roche (2011) Personalisierte Medizin. Kleine Unterschiede, grosse Wirkung. F. Hoffmann-La Roche AG, Basel Roche (2011) Personalisierte Medizin. Kleine Unterschiede, grosse Wirkung. F. Hoffmann-La Roche AG, Basel
go back to reference Roche (2012) Geschäftsbericht 2012. F. Hoffmann-La Roche AG, Basel Roche (2012) Geschäftsbericht 2012. F. Hoffmann-La Roche AG, Basel
go back to reference Roche (2013) Geschäftsbericht 2013. F. Hoffmann-La Roche AG, Basel Roche (2013) Geschäftsbericht 2013. F. Hoffmann-La Roche AG, Basel
go back to reference Rottenkolber D, Hasford J, Stausberg J (2012) Costs of adverse drug events in German hospitals – a microcosting study. Value Health 15:868–875. doi:10.1016/j.jval.2012.05.007 CrossRefPubMed Rottenkolber D, Hasford J, Stausberg J (2012) Costs of adverse drug events in German hospitals – a microcosting study. Value Health 15:868–875. doi:10.1016/j.jval.2012.05.007 CrossRefPubMed
go back to reference Schnee M, Heine T (2008) Weiße Biotechnologie am Kapitalmarkt. DVFA, Frankfurt a. M. Schnee M, Heine T (2008) Weiße Biotechnologie am Kapitalmarkt. DVFA, Frankfurt a. M.
go back to reference Sertkaya A, Birkenbach A, Berlind A, Eyraud J (2014) Examination of clinical trial costs and barriers for drug development. Report prepared for the U.S. Department of Health and Human Services, Eastern Research Group, Lexington Sertkaya A, Birkenbach A, Berlind A, Eyraud J (2014) Examination of clinical trial costs and barriers for drug development. Report prepared for the U.S. Department of Health and Human Services, Eastern Research Group, Lexington
go back to reference Sheridan C (2015) Amgen’s bispecific antibody puffs across finish line. Nat Biotechnol 33:219–221 CrossRefPubMed Sheridan C (2015) Amgen’s bispecific antibody puffs across finish line. Nat Biotechnol 33:219–221 CrossRefPubMed
go back to reference Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7:201–204. doi:10.1016/S1471-4914(01)01986-4 CrossRefPubMed Spear BB, Heath-Chiozzi M, Huff J (2001) Clinical application of pharmacogenetics. Trends Mol Med 7:201–204. doi:10.1016/S1471-4914(01)01986-4 CrossRefPubMed
go back to reference Stahmann KP, Hohmann HP (2013) Vitamine, Nukleotide und Carotinoide. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 127–148 CrossRef Stahmann KP, Hohmann HP (2013) Vitamine, Nukleotide und Carotinoide. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 127–148 CrossRef
go back to reference Steinbüchel A, Raberg M (2013) Polysaccharide und Polyhydroxyalkanoate. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 225–243 CrossRef Steinbüchel A, Raberg M (2013) Polysaccharide und Polyhydroxyalkanoate. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 225–243 CrossRef
go back to reference Syldatk C, Hausmann R (2013) Organische Säuren. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 90–107 Syldatk C, Hausmann R (2013) Organische Säuren. In: Sahm H et al (Hrsg) Industrielle Mikrobiologie. Springer, Heidelberg, S 90–107
go back to reference Thomson Reuters (2012) 2012 CMR international pharmaceutical R&D factbook. Thomson Reuters, London Thomson Reuters (2012) 2012 CMR international pharmaceutical R&D factbook. Thomson Reuters, London
go back to reference Tice DG, Carroll KA, Bhatt KH, Belknap SM, Mai D, Gipson HJ, West DP (2013) Characteristics and causes for Non-Accrued Clinical Research (NACR) at an Academic Medical Institution. J Clin Med Res 5:185–193. doi:10.4021/jocmr1320w PubMedPubMedCentral Tice DG, Carroll KA, Bhatt KH, Belknap SM, Mai D, Gipson HJ, West DP (2013) Characteristics and causes for Non-Accrued Clinical Research (NACR) at an Academic Medical Institution. J Clin Med Res 5:185–193. doi:10.4021/jocmr1320w PubMedPubMedCentral
go back to reference transGEN (2014) Bt-Mais: Ein Risiko für Umwelt. Wirklich? transGEN Kompakt 5, März 2014. 7 http://​www.​transgen. de/pdf/kompakt/mais.pdf. Zugegriffen: 14. April 2015 transGEN (2014) Bt-Mais: Ein Risiko für Umwelt. Wirklich? transGEN Kompakt 5, März 2014. 7 http://​www.​transgen. de/pdf/kompakt/mais.pdf. Zugegriffen: 14. April 2015
go back to reference USDA (2008) U.S. biobased products: market potential and projections through 2025. United States Department of Agriculture (USDA), Washington USDA (2008) U.S. biobased products: market potential and projections through 2025. United States Department of Agriculture (USDA), Washington
go back to reference VDGH (2012) Hightech für das ärztliche Labor. VDGH Verband der Diagnostica-Industrie e. V., Berlin VDGH (2012) Hightech für das ärztliche Labor. VDGH Verband der Diagnostica-Industrie e. V., Berlin
go back to reference Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32:992–1000. doi:10.1038/nbt.3040 CrossRefPubMed Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32:992–1000. doi:10.1038/nbt.3040 CrossRefPubMed
go back to reference Wieland T (2012) Pfadabhängigkeit, Forschungskultur und die langsame Entfaltung der Biotechnologie in der Bundesrepublik Deutschland. In: Fraunholz U, Hänseroth T (Hrsg) Ungleiche Pfade? Innovationskulturen im deutsch-deutschen Vergleich. Waxmann, Münster, S 73–97 Wieland T (2012) Pfadabhängigkeit, Forschungskultur und die langsame Entfaltung der Biotechnologie in der Bundesrepublik Deutschland. In: Fraunholz U, Hänseroth T (Hrsg) Ungleiche Pfade? Innovationskulturen im deutsch-deutschen Vergleich. Waxmann, Münster, S 73–97
go back to reference Woopen C (2013) Personalisierte Medizin – der Patient als Nutznießer oder Opfer? Vorwort in der Tagungsdokumentation der Jahrestagung des Deutschen Ethikrates 2012. Deutscher Ethikrat, Berlin Woopen C (2013) Personalisierte Medizin – der Patient als Nutznießer oder Opfer? Vorwort in der Tagungsdokumentation der Jahrestagung des Deutschen Ethikrates 2012. Deutscher Ethikrat, Berlin
go back to reference Zylka-Menhorn V, Korzilius H (2014) Biosimilars: Das Wettrennen ist in vollem Gange. Dtsch Arztebl 111:A452–A455 Zylka-Menhorn V, Korzilius H (2014) Biosimilars: Das Wettrennen ist in vollem Gange. Dtsch Arztebl 111:A452–A455
Metadata
Title
Anwendende Sektoren und Märkte der Biotechnologie
Author
Julia Schüler
Copyright Year
2016
Publisher
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-47160-9_3